Related Experiment Video
Updated: Jan 23, 2026
08:49
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
11.6K
Abstract:
Patients with non-small cell lung cancer harboring MET exon 14 skipping mutations have commonly been treated with the multikinase inhibitor crizotinib, but more MET-specific therapies are being developed. Two such agents, capmatinib and tepotinib, have demonstrated preliminary efficacy in ongoing phase II trials.
Insights
New MET-specific therapies, capmatinib and tepotinib, show promise for non-small cell lung cancer patients with MET exon 14 skipping mutations. These agents offer alternatives to crizotinib in ongoing phase II trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations presents a specific therapeutic challenge.
- Crizotinib, a multikinase inhibitor, has been a common treatment option for these patients.
- There is a need for more targeted therapies with potentially improved efficacy and specificity.
